Ȩ > ´ÚÅÍÇÏÆ®¼Ò½Ä

 
¾È³çÇϽʴϱî? ´ÚÅÍÇÏÆ®¿¡¼­ °øÁö»çÇ×À» ¾Ë·Áµå¸³´Ï´Ù.
 
2024. 03. 29.
 Á¦12Â÷ ±¹Á¦ÀÌÁ¾À̽ÄÇÐȸ
±Û¾´ÀÌ: °ü¸®ÀÚ  ³¯Â¥: 2013.11.14. 11:32:57   Á¶È¸: 4199
2013³â 11¿ù 10ÀÏ~13ÀϱîÁö ÀϺ» ¿À»çÄ«, ¿À»çÄ«±¹Á¦È¸ÀÇÀå¿¡¼­ Á¦12Â÷ ±¹Á¦ÀÌÁ¾À̽ÄÇÐȸ Çмú´ëȸ°¡ ¼ºÈ²¸® °³ÃֵǾú´Ù.
Âü°¡ÀÚµéÀº Àü¼¼°è¸¦ Æ÷ÇÔÇÏ¿© ¹Ì±¹, À¯·´, È£ÁÖ, ´ºÁú¶õµå, Áß±¹, ÀϺ», Çѱ¹µî¿¡¼­ ¾à 400 ¿©¸íÀÇ ÀÌÁ¾À̽Ŀ¬±¸ °ü·ÃÇÐÀÚµéÀÌ 4ÀÏ°£ 400 ¿©ÆíÀÇ ÀÌÁ¾À̽İü·Ã ¿¬±¸¹ßÇ¥¿Í Ư°­, ½ÉÆ÷Áö¿òµîÀ¸·Î ¿­¶í Çмú´ëȸ°¡ ÁøÇàµÇ¾ú´Ù.
Çѱ¹¿¡¼­µµ ¿©·¯´ëÇп¡¼­ ¸¹Àº ¿¬±¸ÁøÀÌ Âü¼®ÇÏ¿´À¸¸ç ÃÊû°­¿¬, ¿¬±¸¹ßÇ¥¸¦ ½ÃÇàÇÏ¿´´Ù. ƯÈ÷ ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¿¬±¸ÁøÀÌ Çѱ¹ ´ëÇ¥µéÀÇ ÁÖ·ù¸¦ ÀÌ·ç°í ÃÊû°­ÀÇ, ÁÂÀå, ½Ê¿©ÆíÀÇ ¿¬±¸°á°ú¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ¼­¿ï´ëÇб³º´¿ø ÈäºÎ¿Ü°ú¿¡¼­µµ  Development of novel combined anticalcification protocol including immunologic modification for prolonged durability of cardiac xenograft in animal study¿Í In-vivo efficacy for treatment with decellularization, alpha-galactosidase, spacefiller, organic solvent and detoxifixation of GA-fixed cardiac xenograft using alpha-gal mouse implantation model À̶õ ¿¬Á¦¸¦ ¹ßÇ¥ÇÏ¿´´Ù. ±Ý³â¿¡´Â alpha-gal KO pig¿¡ genetic modification ÁøÇàÀÌ ´õ¿í ÇöÀúÇÏ°í, genetically induced disease(agenesis) model°³¹ß, chimerism ¹æ¹ýµµ ´«ºÎ½Ã°Ô ¹ßÀüµÇ¾ú´Ù. Çѱ¹µµ ÀÌ·¯ÇÑ ÀÌÁ¾À̽Ŀ¡¼­ À¯ÀüÀÚ Ã³¸® ±â¼úµéÀÌ »¡¸® Çâ»óµÇ±æ ±â¿øÇÑ´Ù.
LIST  MODIFY DELETE WRITE  





Àüü±Û ¸ñ·Ï 2024. 03. 29.  Àüü±Û: 211  ¹æ¹®¼ö: 1016338
102 Á¦ 63Â÷ ÀϺ»ÈäºÎ¿Ü°úÇÐȸ °ü¸®ÀÚ2010.10.27.4109
101 ÀÌÁ¾Àå±â ½ÉÇ÷°ü°èÀÌÁ¾À̽ݳ¹ß °ü¸®ÀÚ2010.09.08.4147
100 Áß±¹ ¿¬º¯´ëÇÐ º¹Áöº´¿ø ½ÉÀå¼ö¼ú °ü¸®ÀÚ2010.08.21.4384
99 ¼­¿ï´ëÇб³º´¿øÀå ǥâÆÐ ¼ö¿© °ü¸®ÀÚ2010.08.21.4069
98 Á¦ 3Â÷ ¾Æ½Ã¾Æ-ÅÂÆò¾ç ¼Ò¾Æ½ÉÀåÇÐȸ Çмú´ëȸ °ü¸®ÀÚ2010.07.09.4070
97 Áß±¹ Èæ·æ°­¼º ÇϾóºó ¾Æµ¿º´¿ø ½ÉÀå¼ö¼ú °ü¸®ÀÚ2010.06.20.4259
96 Á¦ 90Â÷ ¹Ì±¹ÈäºÎ¿Ü°úÇÐȸ °ü¸®ÀÚ2010.05.08.4096
95 Áß±¹ ÇϾóºó ¾Æµ¿º´¿ø ½ÉÀå¼ö¼ú °ü¸®ÀÚ2010.04.12.4527
94 Á¦ 18Â÷ ¾Æ½Ã¾Æ ½ÉÀåÇ÷°ü ¹× ÈäºÎ¿Ü°úÇÐȸ °ü¸®ÀÚ2010.03.02.4212
93 Æóµ¿¸Æ °íÇ÷¾Ð 2010 °Ü¿ï½ÉÆ÷Áö¿ò °ü¸®ÀÚ2010.02.01.4241
RELOAD WRITE
 1 ¢¸ 11 [12] [13] [14] [15] [16] [17] [18] [19] [20]  ¢º 22